Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inter-Individual Variation and Cardioprotection in Anthracycline-Induced Heart Failure

9 Sept 2021

Abstract excerpt

Anthracyclines are one of the most widely used and effective chemotherapies in oncology, but their most important side effect is the cumulative, dose-related cardiotoxicity leading to congestive heart failure in ~5% of individuals. Methodology and pharmacogenetic studies for predicting which individuals are at high risk and subsequently the development of targeted and individualized cardioprotective plans are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related cognitive impairment studies
Share to Chemotherapy-induced cardiotoxicity and mitigation
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34575190
DOI: 10.3390/jcm10184079

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inter-Individual Variation and Cardioprotection in Anthracycline-Induced Heart FailurePMID 34575190Read ↗

Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity.Semantic proximity Read ↗

The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition.Semantic proximity Read ↗

Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk.Semantic proximity Read ↗

Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer.Semantic proximity Read ↗

Genotyping the risk of anthracycline-induced cardiotoxicity.Semantic proximity Read ↗

Genetic Background in Patients with Cancer Therapy-Induced CardiomyopathySemantic proximity Read ↗

Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytesSemantic proximity Read ↗

Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.Semantic proximity Read ↗

Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.Semantic proximity Read ↗

Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytesSemantic proximity Read ↗

Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.Semantic proximity Read ↗

Anthracycline-mediated cardiomyopathy: Basic molecular knowledge for the cardiologistSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.